Methazolamide
Methazolamide (methazolamide) is a small molecule pharmaceutical. Methazolamide was first approved as Neptazane on 1982-01-01. It is used to treat angle-closure glaucoma and open-angle glaucoma in the USA. The pharmaceutical is active against carbonic anhydrase 7. In addition, it is known to target carbonic anhydrase 14, carbonic anhydrase 1, carbonic anhydrase 12, and carbonic anhydrase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Methazolamide (discontinued: Methazolamide, Neptazane)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methazolamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NEPTAZANE | Lederle Laboratories | N-011721 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| methazolamide | ANDA | 2026-02-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
| angle-closure glaucoma | — | D015812 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | 1 | — | — | 3 | — | 4 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 1 | 1 | — | 2 |
| Hypoxia | D000860 | — | R09.02 | 1 | 1 | — | 1 | — | 2 |
| Motor activity | D009043 | EFO_0003940 | — | 1 | 1 | — | 1 | — | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | 1 | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | — | — | — | 1 | — | — | — | 1 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methazolamide |
| INN | methazolamide |
| Description | Methazolamide is a member of thiadiazoles and a sulfonamide. |
| Classification | Small molecule |
| Drug class | carbonic anhydrase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C |
Identifiers
| PDB | — |
| CAS-ID | 554-57-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL19 |
| ChEBI ID | 6822 |
| PubChem CID | 4100 |
| DrugBank | DB00703 |
| UNII ID | W733B0S9SD (ChemIDplus, GSRS) |
Target
Alternate
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Methazolamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,288 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
90 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use